ストックスクリーナーアプリを入手
2.965
5.27%
-0.165
前日終値:
$3.13
開ける：
$3.18
24時間の取引高:
800.44K
Relative Volume:
0.73
時価総額：
$388.89M
収益：
-
当期純損益:
$-217.44M
株価収益率:
-1.3664
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
+4.40%
1か月 パフォーマンス:
+1.89%
6か月 パフォーマンス:
-32.61%
1年 パフォーマンス:
-65.08%
1日の値動き範囲:
$2.96
$3.1954
1週間の範囲:
$2.895
$3.36
52週間の値動き範囲:
$2.25
$9.77
Prime Medicine Inc Stock (PRME) Company Profile
PRME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.965 | 388.89M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
Comparing Qiagen (NYSE:QGEN) & Prime Medicine (NYSE:PRME) - Defense World
Sumitomo Mitsui Trust Group Inc. Has $9.02 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine (NYSE:PRME) Raised to Sell at StockNews.com - Defense World
Analysts review Prime Medicine Inc’s rating - Knox Daily
Closing Figures: Prime Medicine Inc (PRME)’s Negative Finish at 2.47, Down -1.98 - The Dwinnex
There is no way Prime Medicine Inc (PRME) can keep these numbers up - SETE News
Prime Medicine: Gene Editing Company, Risky Investment (NASDAQ:PRME) - Seeking Alpha
Metric Analysis: Prime Medicine Inc (PRME)’s Key Ratios in the Limelight - The Dwinnex
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.13 - MarketBeat
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13 - Defense World
Nisa Investment Advisors LLC Buys 12,507 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Thermo Fisher to Cut 300 People Across 2 Massachusetts Sites - BioSpace
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm -January 30, 2025 at 12:27 pm EST - Marketscreener.com
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PR Newswire
PBM Prime Therapeutics to Pay $10 Million Antitrust Case Over Price-Fixing Scheme with Express Scripts, Inc. - Policy & Medicine
Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World
Alliance for Regenerative Medicine: Field growing, cost still an issue - BioWorld Online
Prime Medicine Advances Gene Editing and Trials - TipRanks
Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Prime Medicine (NYSE:PRME) Rating Increased to Sell at StockNews.com - Defense World
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $5.26 Million Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Barclays PLC Boosts Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
State Street Corp Buys 43,086 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal 2025 - Investing.com
When Would Be The Best Time To Buy Prime Medicine Inc (NASDAQ: PRME) Stock? - Stocks Register
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Consensus Price Target from Analysts - Defense World
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):